Capricor Therapeutics
CAPR
29 hedge funds and large institutions have $8.95M invested in Capricor Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
32% more capital invested
Capital invested by funds: $6.8M → $8.95M (+$2.15M)
16% more funds holding
Funds holding: 25 → 29 (+4)
1.06% more ownership
Funds ownership: 9.61% → 10.67% (+1.1%)
0% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $1.04M
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HIIFS
26
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| $2K | – | – | – |
|
27
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $2K | – | – | – |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$1.97K | +500 | New |
|
|
JF
29
Jump Financial
Chicago,
Illinois
| – | -$67K | -22,800 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$4K | -1,277 | Closed |
|
31
Citigroup
New York
| – | +$79 | +20 | New |
|
CAPR Hedge Fund Activity: Q1 2022 in Review
29 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2022, worth a combined $8.95M — up 32% from $6.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CAPR positions and 3 closed out — a net gain of 4 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Selective Wealth Management, opening a new position worth an estimated $842K. The largest seller was Susquehanna International Group, cutting an estimated $221K.
- 29 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2022, up from 25 in Q4 2021.
- Funds reported $8.95M of Capricor Therapeutics stock for Q1 2022, up 32% quarter-over-quarter.
- 7 funds opened new Capricor Therapeutics positions in Q1 2022 and 3 closed out, a net change of +4 holders.
- The largest Capricor Therapeutics buyer in Q1 2022 was Selective Wealth Management, an estimated $842K added.
- The largest Capricor Therapeutics seller in Q1 2022 was Susquehanna International Group, an estimated $221K sold.
Based on aggregated 13F filings for Q1 2022.